Results 71 to 80 of about 21,523 (174)
Factores predictores de reperfusión fútil tras tratamiento endovascular de ictus isquémico por oclusión de gran arteria [PDF]
, 2017 A pesar de haber demostrado eficacia abrumadora en pacientes con ictus isquémico por oclusión de gran arteria intracraneal, la evolución clínica en la mitad de los pacientes recanalizados completamente con tratamiento endovascular no es satisfactoria ...
Tajadura Ordóñez, Esther
core
Transfusion, EarlyView.Abstract Background Transfusion‐related alpha‐gal syndrome (TRAGS) has recently been proposed as a cause of allergic transfusion reactions (ATRs) in which alpha‐gal‐specific IgE in sensitized group O (or potentially group A) recipients reacts with epitopes on group B or AB plasma‐containing components.
Mackenzie Foster +9 more
wiley +1 more source
APIXABAN IN THE TREATMENT OF ATRIAL FIBRILLATION: RANDOMIZED TRIALS AND EVERYDAY CLINICAL PRACTICE
Атеротромбоз, 2017 Apixaban is the only NOA the administration of which is associated with a reduction in the incidence of both stroke and major bleeding. Therefore, apixaban is the drug of choice in patients with non-valvular AF, including elderly patients, patients with ...
O. O. Shakhmatova, E. P. Panchenko
doaj +1 more source
Apixaban linearity profile for hydrotropic solubilization
BLDE University Journal of Health Sciences, 2020 A study on the hydrotropic solubility and linearity profile of Apixaban was carried out by using Sodium Salicylate as the solubilizing agent as Apixaban is poorly soluble in water.
Santosh Karajgi, Shripad Potadar
doaj +1 more source
Transfusion, EarlyView.Abstract Background Oral factor Xa (FXa) inhibitors are anticoagulants with no approved reversal agent for use before urgent invasive procedures. Four‐factor prothrombin complex concentrate (4F‐PCC) is used off‐label for this despite limited evidence regarding its effectiveness and safety.
Mohammad Shamiea +8 more
wiley +1 more source
PLoS ONE, 2013 Apixaban is a new oral anticoagulant with a specific inhibitory action on FXa. No information is available on the reversal of the antihemostatic action of apixaban in experimental or clinical settings.
Gines Escolar +9 more
doaj +1 more source
Evaluation of hypoxic tissue using 18F-FMISO PET in a rat model with cerebral stroke [PDF]
, 2016 Traballo fin de mestrado (UDC.CIE). Neurociencia.
Gómez Lado, Noemí
core +1 more source
Nuevos anticoagulantes orales en la prevención de fenómenos tromboembólicos en la fibrilación auricular no valvular [PDF]
, 2013 Atrial fibrillation is the most frequent cardiac arrhythmia in clinical practice. The value of anticoagulation with vitamin K antagonists like warfarin in the prevention of embolic phenomena is widely demonstrated but managing is difficult because of its
Sosa Rosado, José Manuel
core +3 more sources
Advances in cardiac devices and bioelectronics augmented with artificial intelligence
The Journal of Physiology, EarlyView.Abstract figure legend Interfaces between the human heart, diagnostic bioelectronics, artificial intelligence, and clinical care. From left to right: Human heart and biosensor interface; representative waveforms of common diagnostic bioelectronic sensing modalities.
Charles Stark +3 more
wiley +1 more source
Clinical pharmacology consultations and their implementation in clinical decision making
British Journal of Clinical Pharmacology, Volume 92, Issue 4, Page 1069-1077, April 2026.Aims One of the key roles of clinical pharmacologists is to work as consultants for other medical specialties. We wanted to investigate the characteristics of clinical pharmacology consultations, compare the types of consultations from different specialties, and evaluate how well the recommendations given were followed.
Mirjam Kauppila +2 more
wiley +1 more source